Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee

Not Applicable

Completed

• Conditions: Osteoarthritis
• Interventions: Dietary Supplement: flavocoxid 250 mg; Dietary Supplement: flavocoxid 500 mg; Drug: Naproxen

• Registration Number: NCT00435292
• Lead Sponsor: Primus Pharmaceuticals

Brief Summary

Randomized, double-blind, placebo controlled parallel group, multi center study in subjects with moderate-severe osteoarthritis.

Detailed Description

This will be a randomized, double blind, placebo controlled, parallel group, multi-center study in subjects with moderate-severe OA. Subjects will be randomized to receive flavocoxid 250 mg bid, flavocoxid 500 mg bid, naproxen 500 mg bid or placebo in a 2:2:2:1 ratio. Subjects will take study materials twice daily for twelve (12) weeks. After the 12 week visit subjects in the placebo arm will be re-randomized to the two flavocoxid arms. All subjects will then continue on the study for an additional 12 weeks.

Subjects will keep a diary noting date of onset of symptom change (better or worse), adverse events and cost of all aspects of medical care related directly or indirectly to osteoarthritis.

Laboratory studies for inflammatory markers will be drawn and archived at baseline and at the 12 week visit. In addition, a subgroup of subjects will have arthrocenteses performed at baseline and the 12 week visit and the synovial fluid archived for study of intra-articular inflammatory markers.

Study Timeline

• Study Start: 2006-04
• Study First Submitted: 2007-02-12
• Study First Submitted QC: 2007-02-13
• Study First Posted: 2007-02-14
• Primary Completion: 2007-12
• Study Completion: 2007-12
• Status Verified: 2008-11
• Last Update Submitted: 2015-10-19
• Last Update Posted: 2015-10-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

• OA of the Knee
• K-L Grade 2-3
• Positive response to NSAIDS

Exclusion Criteria

• K-L grade 1 0r 4 OA of the knee
• History of GI Bleed within past 5 years
• Chronic bleeding disorder

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
flavocoxid 250 mg	flavocoxid 250 mg	flavonoid mixture
flavocoxid 500 mg	flavocoxid 500 mg	flavonoid mixture
naproxen	Naproxen	nonsteroidal antiinflammatory drug

Trial Locations

Locations (1)

Primus Pharmaceuticals, Inc; 🇺🇸 Scottsdale, Arizona, United States